BioMérieux BIOFIRE Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Becomes First COVID-19 Diagnostic Test to Obtain De Novo FDA Authorization
|
By HospiMedica International staff writers Posted on 19 Mar 2021 |
|
Image: BIOFIRE RP2.1 Panel (Photo courtesy of BioMérieux)
BioMérieux (Marcy-l'Étoile, France) has received US Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE RP2.1 Panel, making it the first SARS-CoV-2 diagnostic test of any kind to be granted De Novo status by US FDA.
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
The panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause of COVID-19 disease). The panel was granted De Novo status by US FDA after having gone through the normal US FDA review pathway outside of the Emergency Use Authorization (EUA) track. The De Novo authorization will be concurrent with the revocation of the US FDA EUA that was obtained on May 1, 2020 for the panel. The BIOFIRE RP2.1 Panel EUA and De Novo kits are identical with the exception of changes to the labeling.
The BIOFIRE RP2.1 Panel allows healthcare providers to quickly identify common respiratory pathogens found in patients presenting with acute respiratory tract infection, using one simple test. The BIOFIRE RP2.1 Panel yields results in approximately 45 minutes using nasopharyngeal swab (NPS) samples in transport media or saline. It runs on the fully automated BIOFIRE FILMARRAY 2.0 and BIOFIRE Torch Systems with only two minutes of sample preparation time.
The De Novo application was supported by a multicenter prospective clinical study in which the performance of the BIOFIRE RP2.1 Panel SARS-CoV-2 assay was evaluated in over 500 specimens against a combined reference of three independent molecular SARS-CoV-2 assays, each with U.S. FDA EUA designation. The BIOFIRE RP2.1 Panel SARS-CoV-2 assay demonstrated positive percent agreement (PPA) of 98.4% and negative percent agreement (NPA) of 98.9%.
“The De Novo authorization of the BIOFIRE RP2.1 Panel demonstrates how BioFire is dedicated to responding to a rapidly-evolving global pandemic with urgency and accuracy. This is the first US FDA De Novo authorized COVID-19 test,” said Pierre Boulud, Chief Operating Officer, Clinical Operations of bioMérieux.
Related Links:
BioMérieux
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Medical-Grade Display
HL2316SHTB
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channel
AI Tools Show Potential to Detect Subtle Signs of Interval Breast Cancer
Interval breast cancers, diagnosed after a negative screening mammogram and before the next scheduled exam, remain an important measure of screening performance and are often more aggressive.... Read more
AI Framework Aims to Turn Medical Care from Reactive to Preventive
Health systems face rising burdens from aging populations, chronic disease, and workforce shortages. Medical artificial intelligence (AI) remains concentrated in diagnosis and decision support, leaving... Read more
Critical Care
view channel
Octopus-Inspired Patch Improves Adhesion for Transdermal Drug Delivery
Transdermal drug delivery requires secure contact between a patch and dynamically moving skin. Everyday bending and stretching can open microgaps that degrade adhesion and reduce dose consistency, limiting... Read more
Multimodal AI System Tracks Early Warning Signs of Mental Health Crisis
In the United States, more than 47,000 people die by suicide each year and more than 10 million seriously consider it, according to the U.S. Centers for Disease Control and Prevention. Yet clinicians often... Read more
Surgical Techniques
view channel
New Transvaginal Transducer Improves Imaging for Gynecology and Early Obstetrics
Transvaginal ultrasound is central to gynecology and early obstetrics, where clinicians must balance deep tissue penetration with high-resolution imaging. Switching probes to achieve this balance can interrupt... Read more
Mobile 3-in-1 Imaging System Advances Intraoperative Navigation
Globus Medical’s Excelsius3D intelligent 3-in-1 imaging system has received the CE Mark for commercial sale in the European Union and the United Kingdom. The addition of Excelsius3D expands the company’s... Read more
Patient Care
view channel
Virtual Reality Helps Claustrophobic Patients Complete Cardiac PET/CT Scans
Anxiety and claustrophobia—intense fear of confined spaces—often prevent patients from completing cardiac positron emission tomography/computed tomography (PET/CT). Aborted scans delay diagnosis, consume... Read more
Weighted Blankets Reduce Anxiety in Hospitalized Adults
Anxiety is common among hospitalized adults and can impair recovery, disrupt sleep, and worsen mental health. Although clinicians often use nonpharmacologic strategies, bedside options that act quickly... Read more
Medical Imaging
view channel
AI Imaging Model Predicts Five-Year Breast Cancer Risk from 3D Mammograms
Breast cancer screening programs often struggle to stratify women by near-term risk, which can lead to missed cancers or unnecessary testing. Forecasting who will develop disease within five years is difficult... Read more
Spleen Imaging Signatures May Reveal Hidden Coronary Artery Disease Risk
Coronary artery disease (CAD) remains a leading cause of death despite major gains in managing traditional risk factors. Clinicians still struggle to quantify residual risk and the upstream biology that... Read more
FDA Clears Automated Musculoskeletal Ultrasound Platform for Arthritis Assessment
Musculoskeletal ultrasound is central to evaluating inflammatory arthritis and other joint conditions, but access is limited by workforce shortages and variability in image acquisition. In the United States,... Read more
Automated Platform Converts Super-Resolution Ultrasound into Vascular Biomarkers
Microvascular dysfunction, an early marker of glaucoma, cancer, and other systemic illnesses, often precedes overt clinical signs yet remains difficult to quantify deep in tissue. Super-resolution ultrasound... Read moreHealth IT
view channel
Registry-Driven Digital Outreach Boosts Use of Heart Failure Medicines
Heart failure affects more than 64 million people worldwide and is linked to high mortality, reduced quality of life, and heavy healthcare use. Although sodium-glucose cotransporter 2 inhibitors are proven... Read more
Nurse-Coordinated Care Model Improves Heart Failure Outcomes
Heart failure imposes heavy mortality, morbidity, and cost burdens worldwide, yet proven therapies remain underused in routine practice. This inadequate uptake contributes to preventable hospitalizations... Read more
Point of Care
view channel
Microneedle Patch Enables At-Home Monitoring of Acute Kidney Injury
Kidney disease is often silent in its early stages, making timely detection difficult outside clinical settings. Early biomarkers such as neutrophil gelatinase–associated lipocalin can require blood draws... Read more
Ultrathin Metasurface Could Bring Quantitative Phase Imaging to Portable Devices
Point-of-care imaging often depends on bulky optical systems that have difficulty visualizing nearly transparent cells and tissues without staining. These limitations can slow diagnosis and restrict use... Read more
Business
view channel
Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award
Severe allergic reactions can escalate rapidly and require prompt epinephrine, yet many at-risk patients do not consistently carry their auto-injector. With food allergies affecting an estimated 220 million... Read more
